Trials / Unknown
UnknownNCT04307979
Acute High Fat Bulletproof Coffee vs Black Coffee on Metabolism, Inflammation and Cognitive Function in Healthy Adults
Impact of Bulletproof Coffee on Metabolism, Inflammation and Cognitive Function
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of British Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will determine whether acute ingestion of a high fat "Bulletproof Coffee" will lead to changes in plasma triglycerides, immune cell function, as well as cognitive function when compared to a black coffee.
Detailed description
In a randomized crossover design, participants will consume a single bulletproof coffee or a single black coffee separated by \~7 days. Each visit commences in the morning after an overnight fast of 10-12 hours, with no exercise the day prior, no coffee consumption the morning of testing, and completion of a food log for dietary duplication prior to visit 2. A fasting blood draw is obtained and cognitive function tests administered, along with questionnaires to assess gastrointestinal distress, arousal, and hunger/fullness before coffee consumption. Following this, one of the coffee beverages is consumed (randomized to each visit). Cognitive testing and questionnaires are completed at 60 minutes after finishing the coffee, another blood draw at 90 minutes, and then cognitive testing, questionnaires and a final blood draw 180 minutes after consuming the coffee. This procedure is repeated during their second experimental visit, in which they consume the remaining coffee based on their randomization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | High-fat coffee | A high fat coffee that consists of 29 grams of added fat from grass fed ghee, and MCT oil. |
| DIETARY_SUPPLEMENT | Black coffee | A regular black coffee with no added caloric content. |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2020-03-13
- Last updated
- 2020-03-13
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04307979. Inclusion in this directory is not an endorsement.